These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34549986)

  • 1. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
    Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
    J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation.
    Vergara-Mendoza M; Gomez-Quiroz LE; Miranda-Labra RU; Fuentes-Romero LL; Romero-Rodríguez DP; González-Ruiz J; Hernández-Rizo S; Viveros-Rogel M
    Antiviral Res; 2020 Aug; 180():104856. PubMed ID: 32579898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
    Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
    Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplexed Simian Immunodeficiency Virus-Specific Paired RNA-Guided Cas9 Nickases Inactivate Proviral DNA.
    Smith LM; Ladner JT; Hodara VL; Parodi LM; Harris RA; Callery JE; Lai Z; Zou Y; Raveedran M; Rogers J; Giavedoni LD
    J Virol; 2021 Nov; 95(23):e0088221. PubMed ID: 34549979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.
    Huang Z; Nair M
    Sci Rep; 2017 Jul; 7(1):5955. PubMed ID: 28729655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
    Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
    EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing.
    Kaminski R; Chen Y; Fischer T; Tedaldi E; Napoli A; Zhang Y; Karn J; Hu W; Khalili K
    Sci Rep; 2016 Mar; 6():22555. PubMed ID: 26939770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection.
    Yin L; Hu S; Mei S; Sun H; Xu F; Li J; Zhu W; Liu X; Zhao F; Zhang D; Cen S; Liang C; Guo F
    Hum Gene Ther; 2018 Nov; 29(11):1264-1276. PubMed ID: 29644868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9.
    Olson A; Basukala B; Lee S; Gagne M; Wong WW; Henderson AJ
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33053801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
    Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness.
    Yoder KE
    Acta Virol; 2019; 63(2):129-138. PubMed ID: 31230441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9: a tool to eradicate HIV-1.
    Bhowmik R; Chaubey B
    AIDS Res Ther; 2022 Dec; 19(1):58. PubMed ID: 36457057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of infectious HIV DNA by CRISPR-Cas9.
    Das AT; Binda CS; Berkhout B
    Curr Opin Virol; 2019 Oct; 38():81-88. PubMed ID: 31450074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplexed
    Ophinni Y; Miki S; Hayashi Y; Kameoka M
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33126728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection.
    Wang Q; Liu S; Liu Z; Ke Z; Li C; Yu X; Chen S; Guo D
    Virus Res; 2018 May; 250():21-30. PubMed ID: 29625148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.
    Bialek JK; Dunay GA; Voges M; Schäfer C; Spohn M; Stucka R; Hauber J; Lange UC
    PLoS One; 2016; 11(6):e0158294. PubMed ID: 27341108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line.
    Liu Y; Jeeninga RE; Klaver B; Berkhout B; Das AT
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
    Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
    Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
    Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
    BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.